23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
03:19 , Jan 19, 2018 |  BC Innovations  |  Strategy

After amyloid

As the Alzheimer’s field is slowly taking on the search for new targets outside of the β amyloid and tau hypotheses, researchers are ramping up exploration of new pathways and looking to the disease’s genetics...
00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
18:23 , Jan 12, 2018 |  BC Week In Review  |  Company News

Denali grants Takeda options to neurology antibodies

Denali Therapeutics Inc. (NASDAQ:DNLI) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) options to co-develop and co-commercialize neurodegenerative disorder candidates ATV:BACE1/Tau, ATV:TREM2 and an undisclosed discovery-stage program. The biotech is to receive $40 million in upfront cash...
23:13 , Jan 5, 2018 |  BC Extra  |  Company News

Denali grants Takeda options to neurology antibodies

Denali Therapeutics Inc. (NASDAQ:DNLI) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) options to co-develop and co-commercialize neurodegenerative disorder candidates ATV:BACE1/Tau, ATV:TREM2 and an undisclosed discovery-stage program. The biotech is to receive $40 million in upfront cash...
19:14 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
00:27 , Nov 15, 2017 |  BC Extra  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing , neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are...